Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
81 hedge funds and large institutions have $757M invested in Mirati Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 13 closing their positions.
146% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 13
85% more capital invested
Capital invested by funds: $408M → $757M (+$348M)
29% more funds holding
Funds holding: 63 → 81 (+18)
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
19% less call options, than puts
Call options by funds: $1.31M | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.1M |
| 3 |
Millennium Management
New York
|
+$10.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.08M |
| 5 |
PC
PointState Capital
New York
|
+$8.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$27.9M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$9.37M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$6.83M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.4M |
| 5 |
DM
Deerfield Management
New York
|
-$4.94M |
MRTX Hedge Fund Activity: Q1 2018 in Review
81 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2018, worth a combined $757M — up 85% from $408M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new MRTX positions and 13 closed out — a net gain of 19 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $32.9M. The largest seller was Broadfin Capital, cutting an estimated $27.9M.
- 81 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2018, up from 63 in Q4 2017.
- Funds reported $757M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2018, up 85% quarter-over-quarter.
- 32 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2018 and 13 closed out, a net change of +19 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2018 was Fidelity Investments, an estimated $32.9M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2018 was Broadfin Capital, an estimated $27.9M sold.
Based on aggregated 13F filings for Q1 2018.